June 5 (Reuters) - Johnson & Johnson's therapy for
advanced multiple myeloma sharply reduced the risk of disease
progression when taken with two standard treatments for the
blood cancer, according to research the company hopes will pave
the way for wider use of the treatment.
Read more
No comments:
Post a Comment